Estimated market cap $2.11BShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Oct 29, 2026, last close Nov 13, 2026.134.00M shares, shares as of Oct 29, 2026CIK 1600620The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
11 buys · 2 sells
$546.4K sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Aurinia Pharmaceuticals Inc's latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Aurinia Pharmaceuticals Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
193
29.7% of shares · 71 added
Latest 10-Q
Q3 2026
What changed in Aurinia Pharmaceuticals Inc's latest quarterly report, compared with the one before.
Filed Oct 30, 2026 · Quarter ended Sep 30, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
No open-market insider trades reported since Sep 10, 2026. Insiders have two business days to file.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
193 funds report AUPH. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 59% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 78.07M reported shares by 133.05M shares, from the company’s SEC filing as of Aug 5, 2026.
283 funds hold the stock.
Q3 2026: 30% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202545%
Q3 202551%
Q4 202555%
Q1 202656%
Q2 202659%
Q3 2026 (so far)30%
Q3 2026. 26 new, 71 added to, 54 trimmed, 117 exited since Q2 2026.
One of these funds reports its values in thousands of dollars; its figures are shown in dollars.
Download CSVEvery fund that holds AUPH, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
No recent congressional trades for this company.
Lobbying
What Aurinia Pharmaceuticals Inc and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q3 2014
11
—
6.02M
$19.3M
Q4 2014
11
0
8.48M
$30.7M
Q1 2015
13
+2
7.61M
$33.2M
Q2 2015
13
0
7.22M
$21.7M
Q3 2015
12
-1
7.11M
$20.1M
Q4 2015
16
+4
6.73M
$16.8M
Q1 2016
17
+1
6.74M
$19.7M
Q2 2016
14
-3
7.07M
$20.1M
Q3 2016
15
+1
4.24M
$12.8M
Q4 2016
25
+10
8.63M
$18.1M
Q1 2017
71
+46
24.37M
$179.8M
Q2 2017
65
-6
23.21M
$142.5M
Q3 2017
62
-3
23.44M
$147.0M
Q4 2017
68
+6
23.83M
$108.0M
Q1 2018
64
-4
21.72M
$112.7M
Q2 2018
67
+3
21.30M
$121.8M
Q3 2018
64
-3
21.51M
$144.6M
Q4 2018
61
-3
22.28M
$151.9M
Q1 2019
78
+17
29.83M
$193.9M
Q2 2019
72
-6
30.32M
$199.5M
Q3 2019
72
0
25.48M
$136.0M
Q4 2019
115
+43
49.03M
$993.3M
Q1 2020
125
+10
60.73M
$881.2M
Q2 2020
132
+7
58.84M
$956.4M
Q3 2020
145
+13
64.98M
$957.5M
Q4 2020
145
0
61.03M
$844.5M
Q1 2021
170
+25
52.58M
$682.8M
Q2 2021
167
-3
49.41M
$640.9M
Q3 2021
167
0
43.86M
$966.8M
Q4 2021
191
+24
43.12M
$984.9M
Q1 2022
183
-8
43.17M
$532.9M
Q2 2022
199
+16
50.79M
$1.1B
Q3 2022
189
-10
55.94M
$420.7M
Q4 2022
192
+3
51.60M
$223.1M
Q1 2023
186
-6
50.81M
$556.8M
Q2 2023
200
+14
50.34M
$487.6M
Q3 2023
198
-2
51.03M
$396.5M
Q4 2023
191
-7
55.67M
$500.5M
Q1 2024
178
-13
58.69M
$295.4M
Q2 2024
171
-7
56.54M
$322.8M
Q3 2024
183
+12
59.05M
$432.6M
Q4 2024
200
+17
58.50M
$525.4M
Q1 2025
215
+15
62.76M
$504.7M
Q2 2025
220
+5
59.04M
$500.2M
Q3 2025
245
+25
66.58M
$735.8M
Q4 2025
260
+15
72.63M
$1.2B
Q1 2026
264
+4
74.02M
$1.1B
Q2 2026
284
+20
78.07M
$1.3B
Q3 2026
193
-91
39.78M
$642.2M
Each point is a quarter-end, from Q3 2014 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (05156V102). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2014) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.